Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy
Cancer Biome and Targeted Therapy · 14.11.2026 · 45-80
DOI: 10.66505/cbtt.v1i4.59 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 14.11.2026. Verfasst von Akanksha Pawar und 6 weiteren Autor:innen. Die Arbeit nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Breast tumors comprise interacting malignant, stromal, immune, and microbial compartments, while gut microbial communities can influence systemic immunity, drug metabolism, and therapeutic response. Emerging evidence therefore positions the microbiome as a potential modifier of breast cancer progression and treatment efficacy rather than merely a passive correlate of disease. Nanotechnology offers experimental approaches to couple tumor-directed drug delivery with selective manipulation of intratumoral or intestinal microbiota. Liposomal, lipid-based, inorganic, biomimetic, and biohybrid platforms have been used to reduce tumor-associated bacteria, alter microbial communities or metabolites, and modify antitumor immune responses. Several platforms further combine microbiota modulation with chemotherapy, immunotherapy, ferroptosis induction, or externally activated treatment. However, improved tumor control cannot necessarily be attributed to microbial modulation because many of these systems independently alter drug exposure, tumor-cell viability, oxidative stress, or immune activity. Evidence for microbiota dependence remains largely preclinical and is frequently derived from experimentally colonized or bacteria-enriched tumor models. Low microbial biomass, contamination risk, interpatient microbiome heterogeneity, methodological variability, ecological consequences of microbial depletion, manufacturing complexity, and the absence of clinical validation further constrain translation. This review critically evaluates microbiome-modulating nanoplatforms in breast cancer, distinguishes microbiota-associated from microbiota-dependent therapeutic effects, and defines the mechanistic, analytical, and clinical evidence needed to establish microbiome targeting as a viable component of precision breast cancer therapy
Förderung
- Indian Council of Medical Research
Zitieren
APA
Pawar, A., Leharwani, M., Gupta, G., Goh, K. W., Sharma, A., Sahebkar, A., & Kesharwani, P. (2026). Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy. Cancer Biome and Targeted Therapy, 45-80. https://doi.org/10.66505/cbtt.v1i4.59
Vancouver
Pawar A, Leharwani M, Gupta G, Goh KW, Sharma A, Sahebkar A, et al. Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy. Cancer Biome and Targeted Therapy. 2026:45-80. doi:10.66505/cbtt.v1i4.59
BibTeX
@article{Pawar2026,
author = {Pawar, Akanksha and Leharwani, Muskan and Gupta, Garima and Goh, Khang Wen and Sharma, Ajay and Sahebkar, Amirhossein and Kesharwani, Prashant},
title = {Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy},
journal = {Cancer Biome and Targeted Therapy},
year = {2026},
pages = {45--80},
doi = {10.66505/cbtt.v1i4.59}
}
EUVIMED